Business Wire

ZYCKO

Share
Zycko Appointed as EMEA-Wide Distributor for Unitrends

Specialist VAD Zycko today announced it has been appointed as EMEA-wide distributor for Burlington, MA based Unitrends . Unitrends is a leader in cloud empowered continuity solutions and this appointment underpins Unitrends’ strategy to accelerate its 100% channel model, and its innovative new partner engagement program, whilst supporting its aggressive growth plans across EMEA, initially covering 14 countries.

David Galton-Fenzi, CEO of Zycko, commented: “We are delighted that Unitrends has chosen Zycko as its pan-EMEA distribution partner. There is a great synergy between our two companies – we both have a focus on networking, cloud continuity and recovery, and we share a common approach to the market.

“Unitrends’ broad support for public, private, and hosted clouds equips its channel partners to meet each customer’s unique requirements today, and paves the way to meet future needs. Unitrends achieved significant momentum with its all-channel sales model, announcing in March 2016 that it grew its cloud business 250% year-on-year. They are looking to replicate that success in the wider EMEA marketplace. At Zycko, we are uniquely placed to help Unitrends achieve that goal, though access to our established pan-EMEA channel network, and experienced sales, marketing and technical teams.”

Mike Dalton, senior vice-president of international sales at Unitrends, said: “We chose Zycko because we wanted a genuine, professional value-added distributor across EMEA. The pan-EMEA availability of Zycko’s support and technical resources, and Zycko’s established reseller network were key factors in our choice. Zycko offers a true EMEA solution with consistency across the regions where Unitrends operates. What Zycko and Rigby Private Equity are trying to build internationally, fits in well with our own expansion goals.”

Significant move forward for RPE

In December 2015, Zycko became part of Rigby Private Equity (RPE). RPE is building an EMEA-wide, high-value, specialist distribution business, with a common proposition and consistent delivery. Value added distributor Wick Hill, is also part of RPE and the combined Wick Hill and Zycko product portfolio encompasses networking, infrastructure, security, communications, storage, access, performance, monitoring and management.

Paul Eccleston, head of RPE, commented: “The appointment of Zycko by Unitrends is a significant step forward for our expansion plans. It also demonstrates that there is a strong need for a pan-EMEA distributor that can work with companies wanting to expand and grow internationally, in partnership with a value added distributor that can deliver technical and sales support consistently across EMEA regions, and give vendors access to an established reseller network.”

Unitrends solutions

Unitrends offers the industry’s broadest portfolio of cloud empowered continuity solutions in a single, super-intuitive platform, delivering unmatched flexibility as needs evolve and providing 100 percent confidence in recovery and business continuity.

The company’s Connected Continuity Platform enables organizations of all sizes to protect their data and assure business continuity for their physical, virtual and cloud-based environments.

About Zycko

Zycko is an international specialist IT distributor of innovative IT solutions, covering technology areas for every part of the business IT infrastructure. Areas Zycko covers include data networking, data storage, virtualisation, cloud, monitoring & management, and data centre infrastructure. Through extensive technology and marketplace knowledge, Zycko executes the due diligence necessary to select leading edge strategic partners and technologies that provide its customers with an opportunity to differentiate in a crowded market.

Zycko’s first-class proven solutions demonstrate Zycko’s significance as a value added IT distributor. Today Zycko has 15 offices across 13 countries, and serves the rest of the world from its UK-based headquarters. To complement this evolution, Zycko delivers first class, sophisticated professional services, accredited training, marketing and business development support to its customers. http://www.zycko.com

About Unitrends

Unitrends is trusted by IT Leaders and Pros who know that in today's digital world protecting their ideas and keeping their business running is non-negotiable. To address the growing volume and value of digital information, the company's award winning portfolio of Continuity Solutions enables customers to capitalize on cloud economics, reduce their overall spend on IT, and have 100% confidence in the recovery point to come. Unitrends' Continuity Solutions are backed by a global customer support team that consistently achieves a 98% satisfaction rating and are sold through a community of thousands of expert technology partners, service providers and resellers worldwide. Learn more at www.unitrends.com

ENDS

Contact:

Zycko
Annabelle Brown
public relations consultant
+44(0)1326 318212
abpublicrelations@btinternet.com .
http://www.zycko.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis

Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release

Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe

Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release

Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news

Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release

Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye